APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Metastatic Melanoma Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Metastatic Melanoma Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174012530326 December 2025191 pages

Choose your research edition.

Industry ResearchMetastatic Melanoma Drug Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Metastatic Melanoma Drug Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Metastatic Melanoma Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Metastatic Melanoma Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Metastatic Melanoma Drug Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Metastatic Melanoma Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Metastatic Melanoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Metastatic Melanoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Metastatic Melanoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Metastatic Melanoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Metastatic Melanoma Drug include Novartis AG, Merck & Co., Inc., Pfizer Inc., Plexxikon Inc., Philogen S.p.A., Pharmis Biofarmaceutica, Lda., Ono Pharmaceutical Co., Ltd., OncoSec Medical Inc. and Oncolytics Biotech Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Metastatic Melanoma Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Metastatic Melanoma Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Metastatic Melanoma Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Metastatic Melanoma Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Metastatic Melanoma Drug Segment by Company

Novartis AG

Merck & Co., Inc.

Pfizer Inc.

Plexxikon Inc.

Philogen S.p.A.

Pharmis Biofarmaceutica, Lda.

Ono Pharmaceutical Co., Ltd.

OncoSec Medical Inc.

Oncolytics Biotech Inc.

Omeros Corporation

NewLink Genetics Corporation

Morphotek, Inc.

Millennium Pharmaceuticals, Inc.

Merck KGaA

Metastatic Melanoma Drug Segment by Type

AGI-134

ALT-801

ALT-803

AMG-232

Others

Metastatic Melanoma Drug Segment by Application

Hospital

Clinic

Others

Metastatic Melanoma Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metastatic Melanoma Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Metastatic Melanoma Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metastatic Melanoma Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Metastatic Melanoma Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Metastatic Melanoma Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Metastatic Melanoma Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Metastatic Melanoma Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Metastatic Melanoma Drug Industry Trends Table 2. Metastatic Melanoma Drug Industry Drivers Table 3. Metastatic Melanoma Drug Industry Opportunities and Challenges Table 4. Metastatic Melanoma Drug Industry Restraints Table 5. Global Metastatic Melanoma Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Metastatic Melanoma Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Metastatic Melanoma Drug Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Metastatic Melanoma Drug Sales Market Share by Manufacturers Table 9. Global Metastatic Melanoma Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Metastatic Melanoma Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Metastatic Melanoma Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Metastatic Melanoma Drug Manufacturers, Product Type & Application Table 13. Global Metastatic Melanoma Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Metastatic Melanoma Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of AGI-134 Table 17. Major Manufacturers of ALT-801 Table 18. Major Manufacturers of ALT-803 Table 19. Major Manufacturers of AMG-232 Table 20. Major Manufacturers of Others Table 21. Global Metastatic Melanoma Drug Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 22. Global Metastatic Melanoma Drug Sales by Type (2021-2026) & (W Units) Table 23. Global Metastatic Melanoma Drug Sales by Type (2027-2032) & (W Units) Table 24. Global Metastatic Melanoma Drug Sales Market Share by Type (2021-2026) Table 25. Global Metastatic Melanoma Drug Sales Market Share by Type (2027-2032) Table 26. Global Metastatic Melanoma Drug Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 27. Global Metastatic Melanoma Drug Revenue by Type (2021-2026) & (W Units) Table 28. Global Metastatic Melanoma Drug Revenue by Type (2027-2032) & (W Units) Table 29. Global Metastatic Melanoma Drug Revenue Market Share by Type (2021-2026) Table 30. Global Metastatic Melanoma Drug Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hospital Table 32. Major Manufacturers of Clinic Table 33. Major Manufacturers of Others Table 34. Global Metastatic Melanoma Drug Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 35. Global Metastatic Melanoma Drug Sales by Application (2021-2026) & (W Units) Table 36. Global Metastatic Melanoma Drug Sales by Application (2027-2032) & (W Units) Table 37. Global Metastatic Melanoma Drug Sales Market Share by Application (2021-2026) Table 38. Global Metastatic Melanoma Drug Sales Market Share by Application (2027-2032) Table 39. Global Metastatic Melanoma Drug Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 40. Global Metastatic Melanoma Drug Revenue by Application (2021-2026) & (W Units) Table 41. Global Metastatic Melanoma Drug Revenue by Application (2027-2032) & (W Units) Table 42. Global Metastatic Melanoma Drug Revenue Market Share by Application (2021-2026) Table 43. Global Metastatic Melanoma Drug Revenue Market Share by Application (2027-2032) Table 44. Global Metastatic Melanoma Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 45. Global Metastatic Melanoma Drug Sales by Region (2021-2026) & (W Units) Table 46. Global Metastatic Melanoma Drug Sales Market Share by Region (2021-2026) Table 47. Global Metastatic Melanoma Drug Sales Forecasted by Region (2027-2032) & (W Units) Table 48. Global Metastatic Melanoma Drug Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Metastatic Melanoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 50. North America Metastatic Melanoma Drug Sales by Country (2021-2026) & (W Units) Table 51. North America Metastatic Melanoma Drug Sales by Country (2027-2032) & (W Units) Table 52. Europe Metastatic Melanoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 53. Europe Metastatic Melanoma Drug Sales by Country (2021-2026) & (W Units) Table 54. Europe Metastatic Melanoma Drug Sales by Country (2027-2032) & (W Units) Table 55. Asia Pacific Metastatic Melanoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 56. Asia Pacific Metastatic Melanoma Drug Sales by Country (2021-2026) & (W Units) Table 57. Asia Pacific Metastatic Melanoma Drug Sales by Country (2027-2032) & (W Units) Table 58. South America, Middle East and Africa Metastatic Melanoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 59. South America, Middle East and Africa Metastatic Melanoma Drug Sales by Country (2021-2026) & (W Units) Table 60. South America, Middle East and Africa Metastatic Melanoma Drug Sales by Country (2027-2032) & (W Units) Table 61. Global Metastatic Melanoma Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Metastatic Melanoma Drug Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Metastatic Melanoma Drug Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Metastatic Melanoma Drug Revenue Market Share by Region (2021-2026) Table 65. Global Metastatic Melanoma Drug Revenue Market Share by Region (2027-2032) Table 66. Novartis AG Company Information Table 67. Novartis AG Business Overview Table 68. Novartis AG Metastatic Melanoma Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Novartis AG Metastatic Melanoma Drug Product Portfolio Table 70. Novartis AG Recent Development Table 71. Merck & Co., Inc. Company Information Table 72. Merck & Co., Inc. Business Overview Table 73. Merck & Co., Inc. Metastatic Melanoma Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Merck & Co., Inc. Metastatic Melanoma Drug Product Portfolio Table 75. Merck & Co., Inc. Recent Development Table 76. Pfizer Inc. Company Information Table 77. Pfizer Inc. Business Overview Table 78. Pfizer Inc. Metastatic Melanoma Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Pfizer Inc. Metastatic Melanoma Drug Product Portfolio Table 80. Pfizer Inc. Recent Development Table 81. Plexxikon Inc. Company Information Table 82. Plexxikon Inc. Business Overview Table 83. Plexxikon Inc. Metastatic Melanoma Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Plexxikon Inc. Metastatic Melanoma Drug Product Portfolio Table 85. Plexxikon Inc. Recent Development Table 86. Philogen S.p.A. Company Information Table 87. Philogen S.p.A. Business Overview Table 88. Philogen S.p.A. Metastatic Melanoma Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Philogen S.p.A. Metastatic Melanoma Drug Product Portfolio Table 90. Philogen S.p.A. Recent Development Table 91. Pharmis Biofarmaceutica, Lda. Company Information Table 92. Pharmis Biofarmaceutica, Lda. Business Overview Table 93. Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Product Portfolio Table 95. Pharmis Biofarmaceutica, Lda. Recent Development Table 96. Ono Pharmaceutical Co., Ltd. Company Information Table 97. Ono Pharmaceutical Co., Ltd. Business Overview Table 98. Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Product Portfolio Table 100. Ono Pharmaceutical Co., Ltd. Recent Development Table 101. OncoSec Medical Inc. Company Information Table 102. OncoSec Medical Inc. Business Overview Table 103. OncoSec Medical Inc. Metastatic Melanoma Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. OncoSec Medical Inc. Metastatic Melanoma Drug Product Portfolio Table 105. OncoSec Medical Inc. Recent Development Table 106. Oncolytics Biotech Inc. Company Information Table 107. Oncolytics Biotech Inc. Business Overview Table 108. Oncolytics Biotech Inc. Metastatic Melanoma Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Oncolytics Biotech Inc. Metastatic Melanoma Drug Product Portfolio Table 110. Oncolytics Biotech Inc. Recent Development Table 111. Omeros Corporation Company Information Table 112. Omeros Corporation Business Overview Table 113. Omeros Corporation Metastatic Melanoma Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Omeros Corporation Metastatic Melanoma Drug Product Portfolio Table 115. Omeros Corporation Recent Development Table 116. NewLink Genetics Corporation Company Information Table 117. NewLink Genetics Corporation Business Overview Table 118. NewLink Genetics Corporation Metastatic Melanoma Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. NewLink Genetics Corporation Metastatic Melanoma Drug Product Portfolio Table 120. NewLink Genetics Corporation Recent Development Table 121. Morphotek, Inc. Company Information Table 122. Morphotek, Inc. Business Overview Table 123. Morphotek, Inc. Metastatic Melanoma Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Morphotek, Inc. Metastatic Melanoma Drug Product Portfolio Table 125. Morphotek, Inc. Recent Development Table 126. Millennium Pharmaceuticals, Inc. Company Information Table 127. Millennium Pharmaceuticals, Inc. Business Overview Table 128. Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Product Portfolio Table 130. Millennium Pharmaceuticals, Inc. Recent Development Table 131. Merck KGaA Company Information Table 132. Merck KGaA Business Overview Table 133. Merck KGaA Metastatic Melanoma Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Merck KGaA Metastatic Melanoma Drug Product Portfolio Table 135. Merck KGaA Recent Development Table 136. Key Raw Materials Table 137. Raw Materials Key Suppliers Table 138. Metastatic Melanoma Drug Distributors List Table 139. Metastatic Melanoma Drug Customers List Table 140. Research Programs/Design for This Report Table 141. Authors List of This Report Table 142. Secondary Sources Table 143. Primary Sources List of Figures Figure 1. Metastatic Melanoma Drug Product Image Figure 2. Global Metastatic Melanoma Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Metastatic Melanoma Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Metastatic Melanoma Drug Sales (2021-2032) & (W Units) Figure 5. Global Metastatic Melanoma Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Metastatic Melanoma Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. AGI-134 Image Figure 9. ALT-801 Image Figure 10. ALT-803 Image Figure 11. AMG-232 Image Figure 12. Others Image Figure 13. Global Metastatic Melanoma Drug Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 14. Global Metastatic Melanoma Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Metastatic Melanoma Drug Sales Market Share by Type (2021-2032) Figure 16. Global Metastatic Melanoma Drug Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 17. Global Metastatic Melanoma Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Metastatic Melanoma Drug Revenue Market Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Others Image Figure 22. Global Metastatic Melanoma Drug Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 23. Global Metastatic Melanoma Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Metastatic Melanoma Drug Sales Market Share by Application (2021-2032) Figure 25. Global Metastatic Melanoma Drug Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 26. Global Metastatic Melanoma Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Metastatic Melanoma Drug Revenue Market Share by Application (2021-2032) Figure 28. North America Metastatic Melanoma Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 29. North America Metastatic Melanoma Drug Sales Market Share by Country (2021-2032) Figure 30. U.S. Metastatic Melanoma Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 31. Canada Metastatic Melanoma Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 32. Mexico Metastatic Melanoma Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 33. Europe Metastatic Melanoma Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 34. Europe Metastatic Melanoma Drug Sales Market Share by Country (2021-2032) Figure 35. Germany Metastatic Melanoma Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 36. France Metastatic Melanoma Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 37. U.K. Metastatic Melanoma Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 38. Italy Metastatic Melanoma Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Netherlands Metastatic Melanoma Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Asia Pacific Metastatic Melanoma Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Asia Pacific Metastatic Melanoma Drug Sales Market Share by Country (2021-2032) Figure 42. China Metastatic Melanoma Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 43. Japan Metastatic Melanoma Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 44. South Korea Metastatic Melanoma Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 45. Southeast Asia Metastatic Melanoma Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 46. India Metastatic Melanoma Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 47. Australia Metastatic Melanoma Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 48. South America, Middle East and Africa Metastatic Melanoma Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 49. South America, Middle East and Africa Metastatic Melanoma Drug Sales Market Share by Country (2021-2032) Figure 50. Brazil Metastatic Melanoma Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 51. South Africa Metastatic Melanoma Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 52. Saudi Arabia Metastatic Melanoma Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 53. Turkey Metastatic Melanoma Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Argentina Metastatic Melanoma Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 55. UAE Metastatic Melanoma Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 56. Egypt Metastatic Melanoma Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Chile Metastatic Melanoma Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 58. Global Metastatic Melanoma Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Metastatic Melanoma Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Figure 61. North America Metastatic Melanoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Figure 63. Europe Metastatic Melanoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Metastatic Melanoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Metastatic Melanoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Metastatic Melanoma Drug Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Metastatic Melanoma Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • AGI-134
  • ALT-801
  • ALT-803
  • AMG-232
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Novartis AG
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Plexxikon Inc.
  • Philogen S.p.A.
  • Pharmis Biofarmaceutica, Lda.
  • Ono Pharmaceutical Co., Ltd.
  • OncoSec Medical Inc.
  • Oncolytics Biotech Inc.
  • Omeros Corporation
  • NewLink Genetics Corporation
  • Morphotek, Inc.
  • Millennium Pharmaceuticals, Inc.
  • Merck KGaA

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Metastatic Melanoma Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Metastatic Melanoma Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Metastatic Melanoma Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Metastatic Melanoma Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Metastatic Melanoma Drug Market Dynamics
  1. 2.1 Metastatic Melanoma Drug Industry Trends
  2. 2.2 Metastatic Melanoma Drug Industry Drivers
  3. 2.3 Metastatic Melanoma Drug Industry Opportunities and Challenges
  4. 2.4 Metastatic Melanoma Drug Industry Restraints
3 Metastatic Melanoma Drug Market by Manufacturers
  1. 3.1 Global Metastatic Melanoma Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Metastatic Melanoma Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Metastatic Melanoma Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Metastatic Melanoma Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Metastatic Melanoma Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Metastatic Melanoma Drug Manufacturers, Product Type & Application
  7. 3.7 Global Metastatic Melanoma Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Metastatic Melanoma Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Metastatic Melanoma Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Metastatic Melanoma Drug Tier 1, Tier 2, and Tier 3
4 Metastatic Melanoma Drug Market by Type
  1. 4.1 Metastatic Melanoma Drug Type Introduction
  2. 4.1.1 AGI-134
  3. 4.1.2 ALT-801
  4. 4.1.3 ALT-803
  5. 4.1.4 AMG-232
  6. 4.1.5 Others
  7. 4.2 Global Metastatic Melanoma Drug Sales by Type
  8. 4.2.1 Global Metastatic Melanoma Drug Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Metastatic Melanoma Drug Sales by Type (2021-2032)
  10. 4.2.3 Global Metastatic Melanoma Drug Sales Market Share by Type (2021-2032)
  11. 4.3 Global Metastatic Melanoma Drug Revenue by Type
  12. 4.3.1 Global Metastatic Melanoma Drug Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Metastatic Melanoma Drug Revenue by Type (2021-2032)
  14. 4.3.3 Global Metastatic Melanoma Drug Revenue Market Share by Type (2021-2032)
5 Metastatic Melanoma Drug Market by Application
  1. 5.1 Metastatic Melanoma Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Metastatic Melanoma Drug Sales by Application
  6. 5.2.1 Global Metastatic Melanoma Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Metastatic Melanoma Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Metastatic Melanoma Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Metastatic Melanoma Drug Revenue by Application
  10. 5.3.1 Global Metastatic Melanoma Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Metastatic Melanoma Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Metastatic Melanoma Drug Revenue Market Share by Application (2021-2032)
6 Global Metastatic Melanoma Drug Sales by Region
  1. 6.1 Global Metastatic Melanoma Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Metastatic Melanoma Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Metastatic Melanoma Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Metastatic Melanoma Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Metastatic Melanoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Metastatic Melanoma Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Metastatic Melanoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Metastatic Melanoma Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Metastatic Melanoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Metastatic Melanoma Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Metastatic Melanoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Metastatic Melanoma Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Metastatic Melanoma Drug Revenue by Region
  1. 7.1 Global Metastatic Melanoma Drug Revenue by Region
  2. 7.1.1 Global Metastatic Melanoma Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Metastatic Melanoma Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Metastatic Melanoma Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Metastatic Melanoma Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Metastatic Melanoma Drug Revenue (2021-2032)
  8. 7.2.2 North America Metastatic Melanoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Metastatic Melanoma Drug Revenue (2021-2032)
  11. 7.3.2 Europe Metastatic Melanoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Metastatic Melanoma Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Metastatic Melanoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Metastatic Melanoma Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Metastatic Melanoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Metastatic Melanoma Drug Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Merck & Co., Inc.
  8. 8.2.1 Merck & Co., Inc. Company Information
  9. 8.2.2 Merck & Co., Inc. Business Overview
  10. 8.2.3 Merck & Co., Inc. Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck & Co., Inc. Metastatic Melanoma Drug Product Portfolio
  12. 8.2.5 Merck & Co., Inc. Recent Developments
  13. 8.3 Pfizer Inc.
  14. 8.3.1 Pfizer Inc. Company Information
  15. 8.3.2 Pfizer Inc. Business Overview
  16. 8.3.3 Pfizer Inc. Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Inc. Metastatic Melanoma Drug Product Portfolio
  18. 8.3.5 Pfizer Inc. Recent Developments
  19. 8.4 Plexxikon Inc.
  20. 8.4.1 Plexxikon Inc. Company Information
  21. 8.4.2 Plexxikon Inc. Business Overview
  22. 8.4.3 Plexxikon Inc. Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Plexxikon Inc. Metastatic Melanoma Drug Product Portfolio
  24. 8.4.5 Plexxikon Inc. Recent Developments
  25. 8.5 Philogen S.p.A.
  26. 8.5.1 Philogen S.p.A. Company Information
  27. 8.5.2 Philogen S.p.A. Business Overview
  28. 8.5.3 Philogen S.p.A. Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Philogen S.p.A. Metastatic Melanoma Drug Product Portfolio
  30. 8.5.5 Philogen S.p.A. Recent Developments
  31. 8.6 Pharmis Biofarmaceutica, Lda.
  32. 8.6.1 Pharmis Biofarmaceutica, Lda. Company Information
  33. 8.6.2 Pharmis Biofarmaceutica, Lda. Business Overview
  34. 8.6.3 Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Product Portfolio
  36. 8.6.5 Pharmis Biofarmaceutica, Lda. Recent Developments
  37. 8.7 Ono Pharmaceutical Co., Ltd.
  38. 8.7.1 Ono Pharmaceutical Co., Ltd. Company Information
  39. 8.7.2 Ono Pharmaceutical Co., Ltd. Business Overview
  40. 8.7.3 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Product Portfolio
  42. 8.7.5 Ono Pharmaceutical Co., Ltd. Recent Developments
  43. 8.8 OncoSec Medical Inc.
  44. 8.8.1 OncoSec Medical Inc. Company Information
  45. 8.8.2 OncoSec Medical Inc. Business Overview
  46. 8.8.3 OncoSec Medical Inc. Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 OncoSec Medical Inc. Metastatic Melanoma Drug Product Portfolio
  48. 8.8.5 OncoSec Medical Inc. Recent Developments
  49. 8.9 Oncolytics Biotech Inc.
  50. 8.9.1 Oncolytics Biotech Inc. Company Information
  51. 8.9.2 Oncolytics Biotech Inc. Business Overview
  52. 8.9.3 Oncolytics Biotech Inc. Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Oncolytics Biotech Inc. Metastatic Melanoma Drug Product Portfolio
  54. 8.9.5 Oncolytics Biotech Inc. Recent Developments
  55. 8.10 Omeros Corporation
  56. 8.10.1 Omeros Corporation Company Information
  57. 8.10.2 Omeros Corporation Business Overview
  58. 8.10.3 Omeros Corporation Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Omeros Corporation Metastatic Melanoma Drug Product Portfolio
  60. 8.10.5 Omeros Corporation Recent Developments
  61. 8.11 NewLink Genetics Corporation
  62. 8.11.1 NewLink Genetics Corporation Company Information
  63. 8.11.2 NewLink Genetics Corporation Business Overview
  64. 8.11.3 NewLink Genetics Corporation Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 NewLink Genetics Corporation Metastatic Melanoma Drug Product Portfolio
  66. 8.11.5 NewLink Genetics Corporation Recent Developments
  67. 8.12 Morphotek, Inc.
  68. 8.12.1 Morphotek, Inc. Company Information
  69. 8.12.2 Morphotek, Inc. Business Overview
  70. 8.12.3 Morphotek, Inc. Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Morphotek, Inc. Metastatic Melanoma Drug Product Portfolio
  72. 8.12.5 Morphotek, Inc. Recent Developments
  73. 8.13 Millennium Pharmaceuticals, Inc.
  74. 8.13.1 Millennium Pharmaceuticals, Inc. Company Information
  75. 8.13.2 Millennium Pharmaceuticals, Inc. Business Overview
  76. 8.13.3 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Product Portfolio
  78. 8.13.5 Millennium Pharmaceuticals, Inc. Recent Developments
  79. 8.14 Merck KGaA
  80. 8.14.1 Merck KGaA Company Information
  81. 8.14.2 Merck KGaA Business Overview
  82. 8.14.3 Merck KGaA Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Merck KGaA Metastatic Melanoma Drug Product Portfolio
  84. 8.14.5 Merck KGaA Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Metastatic Melanoma Drug Value Chain Analysis
  2. 9.1.1 Metastatic Melanoma Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Metastatic Melanoma Drug Production Mode & Process
  6. 9.2 Metastatic Melanoma Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Metastatic Melanoma Drug Distributors
  9. 9.2.3 Metastatic Melanoma Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst